However, further investigations are needed to develop an optimal PSMA/GRPR-targeting heterodimer with high affinity to both targets, together with a preferable pharmacokinetic profile with high uptake and long retention in the tumor, low uptake in normal tissue and fast blood clearance. The gene discussed is FOLH1; the disease is neoplasm.